<DOC>
	<DOCNO>NCT02305888</DOCNO>
	<brief_summary>The objective trial investigate Safety LEO 43204 0.018 % , 0.037 % 0.1 % actinic keratosis apply daily three consecutive day face/chest , scalp trunk/extremities , respectively .</brief_summary>
	<brief_title>Safety LEO 43204 Actinic Keratosis Applied Face/Chest , Scalp Trunk/Extremities , Respectively</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Subjects 5 20 clinically typical , visible , discrete , nonhyperkeratotic nonhypertrophic AKs within select treatment area sundamaged skin either : The full face The full balding scalp A contiguous area approximately 250 cm2 trunk extremity Location treatment area ( full face , full balding scalp chest ) within 5 cm incompletely heal wound within 5 cm suspect basal cell carcinoma ( BCC ) SCC . Previously assign treatment clinical trial previously participate clinical trial LEO 43204 programme . Treatment ingenol mebutate gel select treatment area within last 12 month Lesions treatment area : atypical clinical appearance ( e.g . cutaneous horn ) and/or , recalcitrant disease ( e.g. , respond cryotherapy two previous occasion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>